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Stools from tourists from Europe and North America who acquired diarrhea in Mombasa
(Kenya), Goa (India), or Montego Bay (Jamaica) were examined for enteric pathogens. Entero-
toxigenic Escherichia coli (ETEC) was the most common pathogen (25%) identified in the 3
locations. Isolation of Shigella species was more frequent in Goa and Mombasa than in Montego
Bay (10%, 9%, and 0.3%, respectively; P , .005). Viruses (rotaviruses and enteric adeno-
viruses) were found in 9% of travelers to the 3 areas. Of 275 ETEC isolates in this study, 158
(57%) produced a defined colonization factor antigen (CFA). Coli surface 6 (CS6) was the
most frequent and was found in 41%–52% of CFA/CS-positive ETEC isolates. The frequency
of resistance among bacterial enteropathogens to traditional antimicrobial agents was particu-
larly high throughout the study period in all 3 regions. Quinolones were active against the
bacterial enteropathogens in the 3 sites.
Travelers’ diarrhea occurs after exposure to enteric pathogens
during international relocation. Most episodes are self-limiting,
and the causal pathogens usually do not cause persistent damage
to the intestines. Travelers’ diarrhea resembles endemic pedi-
atric diarrhea in the host countries [1]. Both travelers and chil-
dren are highly susceptible to the prevalent pathogens found in
tropical developing countries as a result of environmental con-
tamination, inadequate water supply, and poor sanitation and
hygiene.
The prevalence of etiologic agents that cause travelers’ diar-
rhea differs from area to area. For example, in Latin America,
enterotoxigenic Escherichia coli (ETEC) is widely prevalent,
with rates up to 40% [2, 3], and shows seasonal patterns in some
areas [4]. In contrast, in Southeast Asia, ETEC less commonly
(10%) [3] causes travelers’ diarrhea. Other regional differences
have been found among enteric pathogens isolated from trav-
elers with diarrhea. Rotavirus infection is common in travelers
to Mexico [5], and parasites have been commonly identified
in travelers to Russia [6] and Nepal [7]. Information about the
predominant organisms is critical in developing recommenda-
tions for management and to determine the potential value of
enteric vaccines in the prevention of diarrhea. The present
study was part of an international collaborative study of travelers’
diarrhea designed to investigate the epidemiology, etiology, and
socioeconomic impact of acute diarrhea among travelers visit-
ing Mombasa (Kenya) [8], Goa (India) [8], or Montego Bay
(Jamaica) [9]. Socioeconomic impact of travelers’ diarrhea was
analyzed and discussed in 2 associated publications [8, 9].
Methods
Setting. The study was conducted in 3 sites—Mombasa, Goa,
and Montego Bay—between March 1996 and July 1998. In Goa,
studies did not take place between May and September because of
lack of tourism during the rainy season. The study population was
primarily tourists from Europe and North America [8, 9].
Case definition. Classic diarrhea was defined in the study as the
passage of>3 unformed stools in 24 h plus the development of>1
symptom of enteric infection (fever, abdominal pain or cramps, in-
creased intestinal gas, nausea, vomiting, or passage of bloody stools).
Moderate diarrhea was defined as passage of 1 or 2 unformed stools
with>1 additional enteric symptom or as passage of>2 unformed
stools without additional symptoms. Mild disease was defined as
passage of 1 or 2 unformed stools without enteric symptoms.
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Recruitment. We placed advertisements at numerous hotels in
Kenya, India, and Jamaica, and physicians were introduced to the
travelers at welcome parties sponsored by the hotels. All stool sam-
ples were collected in hotel clinics established to evaluate and treat
patients with diarrheal diseases. Staff from each selected local clini-
cal laboratory received training in standardized methods. Travelers
reporting with acute diarrhea within 48 h of onset who had not used
antimicrobial agents in the past 7 days were invited to provide a
stool sample. From Monday through Friday, stool samples went di-
rectly without transport medium to the project laboratory and were
processed within 4 h. On weekends, transport medium (Culture
& Sensitivity Media; Meridian Diagnostics) was used, and stools
were processed on the Monday after collection.
Laboratory methods. Stool samples in cases of diarrhea were
submitted to a local laboratory in each area, which was staffed by
trained microbiology staff who used common procedures for etiol-
ogy. Stools were examined for enteric protozoal parasites, including
Giardia lamblia, Cryptosporidia species, and Entamoeba histolytica,
by use of EIAs (Alexon). Adenoviruses and rotaviruses were de-
tected by commercial ELISA kits (Premier Rotaclone and Adeno-
clone; Meridian Diagnostics). Cultures for enteric bacteria were
completed by using 6 standard media: MacConkey, Tergitol, Hek-
toen enteric, Yersinia, TCBS, and Campylobacter agar plates. Five
E. coli colonies were saved on peptone stabs for each patient for
enterotoxin analysis in Houston. Heat-stable (ST) and heat-labile
(LT) E. coli were detected by use of oligonucleotides labeled by T4
polynucleotide kinase and 32P-ATP [10].
Various colonization factor antigens (CFAs) were characterized,
as described elsewhere [11]. ETEC were first grown on CFA agar
plates. After incubation at 37C overnight, the expression of ETEC
colonization factors was determined by dot blot test, using mono-
clonal antibodies specific for CFA/I, CFA/III, coli surface (CS) 1,
CS3, CS4, CS5, and CS6. Isolates expressing CS3 alone or in con-
junction with CS1 or CS2 were considered to be CFA/II. Isolates
expressing CS6 alone or with CS4 or CS5 were considered to be
CFA/IV. All bacterial isolates were identified by the API 20E system
(bioMe´rieux Vitek). Antimicrobial susceptibility tests were done with
bacterial pathogens, using the disk diffusion method of the National
Committee for Clinical Laboratory Standards [12]. E. coli ATCC
25922 and Staphylococcus aureus ATCC 259213 were tested as
control strains. The following antimicrobials (all supplied by BBL
Microbiology Systems) were tested for organism susceptibility:
ampicillin (Am-10), chloramphenicol (C-30), doxycycline (D-30),
furazolidone (FX-100), gentamicin (GM-10), ofloxacin (OFX-5),
streptomycin (S-10), sulfisoxazole (G-0.25), tetracycline (TE-30),
trimethoprim-sulfamethoxazole (SXT), and trimethoprim (TMP-5).
Statistical analysis. Statistical analyses were done to define the
significance of differences observed. Contingency tables were made
containing information on the enteric pathogen, severity of illness,
and CFA type in different sites. We used Fisher’s exact test for com-
puter analysis of data (Stata software, version 6.0) for different groups
and pathogens. P , :05 was accepted as statistically significant.
Results
Pathogens identified in patients with diarrhea by the regions
studied are shown in table 1. ETEC was the most common patho-
gen identified in the 3 locations. ETEC was significantly more
common in Mombasa than in Goa (35% vs. 24%; P ¼ :0016)
or in Montego Bay (35% vs. 12%; P , :0001) and significantly
more common in Goa than in Montego Bay (24% vs. 12%;
P , :001). Shigella species pathogens were more frequently
isolated in Goa and Mombasa than in Montego Bay (10%, 9%,
and 0.3%, respectively; P , :005). In Montego Bay, stools were
negative for an enteric pathogen more often than at the other study
sites (68% vs. 45% and 47%, respectively; P , :001). Rota-
viruses were found in 68 (6%) of 1079 patients with diarrhea
and were the second most common enteropathogen in Mon-
tego Bay (8%). Mixed infections (infection with .1 enteric
pathogen) were more common in Goa (11%) and Mombasa
(6%) then in Montego Bay (5%). Isolation of Shigella species
along with ETEC was the most common mixed infection in
Goa, occurring in 7 patients, followed by Salmonella species
with ETEC, occurring in 5 patients. Mixed infection of Shigella
species and ETEC was the most common type in Mombasa (6
cases) followed by 3 cases of dual infection with Vibrio species
and ETEC. Campylobacter species plus ETEC were found in
2 patients, and infection with Salmonella species and ETEC
(2 cases) was identified in Montego Bay.
We pooled the data from the 3 sites to see whether there was a
relationship between severity of diarrhea and infection by an en-
teric pathogen (table 2). There was no apparent increase in iden-
tification rates for enteropathogens in patients with more severe
diarrhea. Although not included in the table, the pathogen detec-
tion rate in severe diarrhea cases (.6 unformed stools) in the 3
areas of study were similar: Goa, 60%; Mombasa, 57%; and
Montego Bay, 51%.
Elsewhere, we described demographic characteristics of the
subjects, including age, sex, country of origin, and sample col-
lection time [8, 9]. Seasonal distribution of enteric pathogens
Table 1. Enteric pathogens identified in international travelers to
Montego Bay, Jamaica; Goa, India; and Mombasa, Kenya.
Identified
enteropathogen
Mombasa
(n = 464)
Goa
(n = 293)
Montego Bay
(n = 322)
Total
(N = 1079)
Aeromonas species 10 (2) 10 (3) 0 20 (2)
Campylobacter species 21 (5) 8 (3) 16 (5) 45 (4)
ETEC 164 (35) 73 (24) 38 (12) 275 (25)
Plesiomonas species 8 (2) 20 (7) 0 28 (3)
Salmonella species 13 (3) 30 (10) 25 (8) 68 (6)
Shigella species 40 (9) 30 (10) 1 (0.3) 71 (7)
Vibrio speciesa 16 (3) 16 (5) 1 (0.3) 33 (3)
Adenovirus 15 (3) 6 (2) 10 (3) 31 (3)
Rotavirus 26 (6) 16 (5) 26 (8) 68 (6)
Giardia lamblia 0 6 (2) 2 (0.6) 8 (0.7)
Entamoeba histolytica 0 14 (5) 2 (0.6) 16 (1)
Cryptosporidium species 0 6 (2) 1 (0.3) 7 (0.6)
Mixed infection 30 (6) 31 (11) 16 (5) 77 (7)
No pathogen detected 218 (47) 132 (45) 220 (68) 570 (53)
NOTE. Data are no. (%) of patients. EHEC, enterotoxigenic Escherichia
coli.
a No Vibrio cholera 01 detected.
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identified in Montego Bay and Mombasa over the year of study
was evaluated. Studies were suspended during 5 months of the
year in Goa. Enteric bacterial infection showed a peak occurrence
from February through April in Jamaica (range, 12%–40%),
whereas rotaviruses were more common between October and
March (range, 5%–8%). However, most cases of Shigella species
infection were identified between May and July in Kenya (range,
26%–41%). ETEC did not show a seasonal trend in Montego
Bay or Mombasa.
Table 3 shows the distributions of different enterotoxigenic
phenotypes among ETEC isolated in the 3 areas. ST-only toxin
was identified in 83 (51%) of 164 ETEC isolates from Mombasa
visitors. LT-only was the most common toxin type detected
in patients who visited Montego Bay (22 [58%] of 38 ETEC
isolates identified). ST/LT production was the most common
ETEC type seen in travelers to Goa (found in 33 [45%] of
73 ETEC isolates). CFAs were identified in 158 (57%) of the
275 ETEC strains studied.
As shown in table 3, the highest CFA frequency was observed
among ST-only ETEC (found in 73 [63%] of all 115 ST-only
ETEC), followed by ST/LT-producing strains (50 [56%] of 90)
and LT-only producers (35 [50%] of 70 LT-only ETEC strains
were CFA positive). The 2 most commonly identified CFA/CS
types were CS6 (alone or with CS4 or CS5) and CS3 (alone or
with CS1 or CS2). Of 110 CFA-positive ETEC strains in Mom-
basa, 53 (48%) were CS6 positive (alone or with CS4 or CS5).
CS6 (alone or with CS4 or CS5) was identified in 9 (41%) of 22
CFA-positive ETEC strains in Goa. CS6 alone or with CS4 or
CS5 was identified in 14 (54%) of 26 CFA-positive ETEC
strains in Montego Bay. In Mombasa, 37 (34%) of 110 CFA-
positive ETEC strains were CS3 positive (alone or in combina-
tion with CS1 or CS2). Eight (36%) of 22 CFA-positive ETEC
strains isolated in Goa were CS3 positive (alone or with CS1 or
CS2). In Montego Bay, 6 (23%) of 26 CFA-positive ETEC
strains were CS3 positive (alone or with CS1 or CS2).
Antimicrobial susceptibility test results for the enteropatho-
gens isolated are given in figure 1. The frequency of resistance to
traditional antimicrobial agents was particularly high through-
out the study period in all 3 regions. Multidrug resistance (resis-
tance to>3 antimicrobial agents) was demonstrated among 30%,
68%, and 69% of bacterial enteropathogens in Mombasa, Goa,
and Montego Bay, respectively. The proportions of Salmonella
species resistant to chloramphenicol, furazolidone, trimethoprim/
sulfamethoxazole, trimethoprim, and tetracycline were signifi-
cantly higher in Goa (P , :05, x2 test). Furazolidone and strepto-
mycin resistance among Shigella isolates occurred most commonly
in Goa. ETEC strains isolated from travelers to Goa were more
resistant to ampicillin than those isolated at the other sites (P ,
:05, x2 test). Resistance frequencies were important at all 3
sites, without obvious differences for chloramphenicol (28%–
62%), doxycycline (46%–57%), or trimethoprim (64%–79%).
A low frequency of resistance to fluoroquinolone and ofloxacin
(0.3%–5%) was found in all 3 regions.
Discussion
ETEC is the most common enteric pathogen infecting trav-
elers after arrival in developing tropical countries [3]. In the pres-
ent study, ETEC was found in 25% of the stool samples from
patients with travelers’ diarrhea in Mombasa and Goa but only
Table 2. Severity of diarrhea and pathogens isolated in Montego Bay, Jamaica; Goa, India; and
Mombasa, Kenya.
Parameter
Mild or moderate
nonclassic diarrhea
(n = 97)
Classic illness: no. of unformed stools
passed in 24 h before enrollment
3–5
(n = 334)
6–9
(n = 414)
>10
(n = 234)
Pathogen identifieda
Aeromonas species 1 (1) 4 (1) 9 (2) 6 (3)
Campylobacter species 0 12 (4) 14 (3) 15 (6)
ETECb 38 (39) 73 (22) 103 (25) 58 (25)
Plesiomonas species 1 (1) 4 (1) 15 (4) 8 (3)
Salmonella species 4 (4) 17 (5) 26 (6) 22 (9)
Shigella species 7 (7) 14 (4) 23 (5) 17 (7)
Vibrio species 0 3 (0.8) 12 (3) 10 (4)
Adenovirus 3 (3) 7 (2) 9 (2) 12 (5)
Rotavirus 8 (8) 17 (5) 20 (5) 25 (11)
Giardia lamblia 0 4 (1) 3 (0.7) 1 (0.4)
Entamoeba histolytica 2 (2) 2 (0.6) 10 (2) 3 (1)
Cryptosporidium species 1 (1) 4 (1) 1 (0.2) 1 (0.4)
Subjects with pathogen identified 51 (53) 137 (41) 192 (46) 134 (57)
No pathogen detected 48 (49) 201 (60) 227 (55) 103 (44)
NOTE. Data are no. (%) of patients. ETEC, enterotoxigenic Escherichia coli.
a Some subjects had multiple infections.
b Three strains are missing from each ETEC classification.
Enteric Pathogens in International TravelersJID 2002;185 (15 February) 499
in 12% (38 isolates) in Montego Bay. Montego Bay is consid-
ered a moderate-risk area for travelers’ diarrhea, and rates of bac-
terial infection would be expected to be lower than in high-risk
areas of Latin America, Africa, and Southeast Asia.
ETEC may cause more than the 25% of occurrence that we
found in the study areas. We previously used the multiplex poly-
merase chain reaction assay to help establish the importance of
ETEC travelers’ diarrhea [13]. In that study of travelers to Mon-
tego Bay, we found an ETEC rate double that found by use of
the standard DNA hybridization procedure used in the present
study. Undoubtedly, an important amount of otherwise pathogen-
undetected diarrhea in high-risk areas is caused by ETEC. In
the present study, ETEC did not show seasonal occurrence pat-
terns in Jamaica and Kenya, which agrees with a previous study
of pathogens in travelers’ diarrhea in Jamaica [9]. A seasonal
pattern of ETEC infection has been seen in other areas, includ-
ing Mexico [4] and Morocco [14].
In a separate study, we looked at the prevalence of entero-
aggregative E. coli as a cause of travelers’ diarrhea by using
the HEp-2 cell assay [15] in 3 populations: in Goa (the same
population included in this study); Ocho Rios, Jamaica (a re-
gion of Jamaica different from that in this study); and Guadala-
jara, Mexico. Enteroaggregative E. coli was identified in 26% of
the travelers’ diarrhea cases and was second to ETEC as the
most common enteropathogen identified in world studies.
In the present study, non-ETEC bacterial enteric pathogens
(Salmonella, Shigella, Campylobacter, Aeromonas, and Vibrio
species) were isolated from 265 (25%) of 1079 patients, and G.
lamblia, E. histolytica, and Cryptosporidia were identified in 31
(3%) of 1079 and rotaviruses and adenoviruses in 99 (9%) of
1079 patients with diarrhea. In Montego Bay, rotaviruses were
the second most common enteric pathogen in persons with trav-
elers’ diarrhea (8% of cases vs. 12% of ETEC). The fact that
there were similar detection rates in classic mild and moderate
travelers’ diarrhea suggests that the 3 degrees of travelers’ diar-
rhea are different clinical expressions of the same enteric infec-
tion. Mixed infections were encountered in 5%–11% of patients
in the study. The distribution of pathogens in mixed infections
appeared to reflect the relative importance of individual etio-
logic agents in the area studied. There did not appear to be a
special relationship between pathogens.
Because we do not have total traveler numbers for each site,
it was not possible to calculate the incidence of travelers’ diar-
rhea in the regions. In the present study, we found no relation-
ship between intensity and severity of clinical illness in patients
with enteric symptoms according to the presence or absence of
a specific enteric infection. The percentage of subjects with en-
teric infection by a specific enteropathogen, including ETEC
with its variation in toxin types, Salmonella species, and Shigella
species, did not differ between those with mild or moderate non-
classic diarrhea and variable degrees of severity of classic travelers’
diarrhea. This suggests that travelers with mild enteric symptoms
are as commonly infected with an enteric pathogen as those with
more intense diarrheal illness.
Other studies have shown that a natural ETEC immunity oc-
curs as people remain at risk for infection [16]. This finding has
given researchers encouragement that a protective ETEC vac-
cine might be developed, and a number of ETEC vaccine candi-
dates are currently under development. It has been concluded
that a human ETEC vaccine should be given orally to evoke both
Table 3. Colonization factor antigen (CFA) types among enterotoxigenic Escherichia coli (ETEC) strains isolated from travelers to Mombasa,
Kenya; Goa, India; and Montego Bay, Jamaica.
CFA type
Heat stable only Heat labile only Heat stable and heat labile
Mombasa Goa Montego Bay Mombasa Goa Montego Bay Mombasa Goa Montego Bay
ETEC 83 22 10 30 18 22 51 33 6
No CFA 25 15 2 14 12 9 15 24 1
Any CFA+ 58 7 8 16 6 13 36 9 5
CFA/I 4 (7)a 0 1 (13) 0 0 3 (23) 0 1 (11) 1 (20)
CS1CS3 15 (26) 1 (14) 2 (25) 1 (6) 0 0 10 (28) 1 (11) 0
CS2CS3 1 (2) 1 (14) 0 0 2 (33) 1 (8) 8 (22) 2 (22) 0
CS3 0 1 (14) 0 0 0 1 (8) 2 (6) 0 2 (40)
CFA/III 1 (2) 0 0 3 (19) 1 (17) 0 0 2 (11) 0
CS4CS6 1 (2) 0 0 0 0 0 2 (6) 0 0
CS5CS6 2 (3) 0 0 0 1 (17) 1 (8) 0 1 (11) 0
CS6 30 (52)b 4 (57) 4 (50) 6 (38)c 1 (17) 7 (54) 12 (33) 2 (22) 2 (40)
Other CFA 4 (7)d 0 1 (13)e 6 (38)f 1 (17)g 0 2 (6)h 0 0
NOTE. Data are no. of strains; parenthetical values are percentages. CFA+, ETEC isolate tested positive for CFA; CS, coli surface.
a No. of any CFA+ isolates was used as a denominator in the category.
b One strain was positive for both CS6 and CFA/III.
c Three strains were positive for both CS6 and CFA/III.
d Putative colonization factor 166 (PCF166) (4 strains).
e PCF159 (1 strain).
f CS7 (3 strains), CS17 (3 strains).
g CS17 (1 strain).
h PCF159 (2 strains).
Jiang et al.500 JID 2002;185 (15 February)
anticolonization and antitoxic immune responses locally in the
gut [17]. The present study provides information that may be use-
ful when the ideal approach for immunologic control of trav-
elers’ diarrhea is considered. At least one of the most promising
vaccine candidates uses cholera toxin B-subunit [18], which is
immunologically and physiologically related to LT of ETEC.
Anti-LT immunity does not protect against ETEC producing
ST only, and ST is not immunogenic unless coupled to a carrier
[19]. It has not been possible to synthesize ST toxoids that
induce a good neutralizing antibody response without residual
toxicity [19].
Of 275 ETEC isolates seen in this study, 115 (42%) produced
ST only and would not be expected to be prevented by an anti-
LT vaccine. ETEC expressing LT alone was the most common
enterotoxin type found in Montego Bay (58%). To be effective,
vaccine candidates should probably contain a number of ETEC
CFAs. In all, 158 (57%) of 275 ETEC isolates in the present
study produced defined CFAs. This is a higher CFA rate than
that seen in studies in South America, including Argentina [11]
and Chile [20]. In the study in Chile [20], a CFA was found in
23% of ETEC isolates. CFA/II was the principal adhesin type
among ETEC in 2 South America countries [11, 20], and a study
in Peru demonstrated the importance of CFA/IV [21]. For a vac-
cine designed for Mombasa, Goa, and Montego Bay, based on
findings in the present study, the preparation should optimally
include CFA/II (CS3 is the most important) and CFA/IV (CS6
is the most important) components. CS6 was commonly iden-
tified in ST-only ETEC producers in the present study (52% in
Mombasa, 57% in Goa, and 50% in Montego Bay). Thus, on the
basis of our results, we believe that an ETEC vaccine for wide-
spread use in developing countries should also include CS6 and
CS3. A vaccine candidate currently under development contains
a combination of CTB and CFA/I and CS1-CS5 on inactivated
bacteria. In the present study, 15% of ETEC isolated from all
sites were LT negative and did not produce detectable CFAs.
Most LT-negative, CFA-negative ETEC isolates were from
Mombasa and Goa (15% and 21%, respectively), and 5% were
from Montego Bay. An LT/CFA vaccine would not be expect-
ed to protect against this proportion of ETEC diarrhea and ob-
viously not against other non-ETEC enteric pathogens.
Trimethoprim resistance is widespread among bacterial en-
teropathogens worldwide, rendering this drug no longer effec-
tive for managing travelers’ diarrhea. ETEC, Salmonella species,
and Shigella species isolated from 3 areas in the present study
showed high-level resistance to trimethoprim and trimethoprim/
sulfamethoxazole (51%), ampicillin (50%), doxycycline (54%),
and gentamicin (39%). We have no explanation for the lower
rate of multiantimicrobial resistance found in enteric pathogen
Figure 1. Proportion (%) of isolates resistant to antimicrobials, by geographic area. In total, 246 isolates were tested by the disk diffusion
method for antimicrobial susceptibility. SXT, trimethoprim-sulfamethoxazole; TMP-5, trimethoprim; TE-30, tetracycline; G-0.25, sulfisoxazole;
S-10; streptomycin; OFX-5, ofloxacin; GM-10, gentamicin; FX-100, furazolidone; D-30, doxycycline; C-30, chloramphenicol; and Am-10,
ampicillin.
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isolates in Mombasa. Although resistance to fluoroquinolones
has been reported among Salmonella typhi in India [22], and
resistance to fluoroquinolones among Campylobacter isolates
in Thailand [23] and Spain [24] has been reported, fluoroquino-
lones remained active in vitro against bacterial enteropathogens
causing travelers’ diarrhea in the 3 areas that we studied. On the
basis of our findings, we believe that drugs of this class should
be considered to be the drugs of choice for treatment of travel-
ers’ diarrhea in adults in most regions of the world. For travel to
areas where fluoroquinolone-resistant pathogens are common
(e.g., Thailand), azithromycin may be the preferred antimicro-
bial therapy [23].
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